<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:department>Biology</gtr:department><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/05B94338-C10A-4B86-B943-018DA740A8EC"><gtr:id>05B94338-C10A-4B86-B943-018DA740A8EC</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Denis</gtr:otherNames><gtr:surname>Ryan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901002"><gtr:id>9E697C76-5095-4CDD-9468-702C025B1B56</gtr:id><gtr:title>Optimisation of the 2A Co-expression System for Gene Therapies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901002</gtr:grantReference><gtr:abstractText>Gene therapy supplies your cells with genes either to replace faulty ones, or to supply genes that can combat other forms of disease. These genes are then translated into proteins. Often, however, a number of different proteins (and hence genes) are required for successful therapy. This work is designed to develop a system whereby multiple genes can be strung together to form a single gene: a multi-gene. It is much easier and safer to introduce one gene via gene therapy, than try to introduce many individual genes into a cell. The chances of this new type of multi-gene being able to produce all of its different proteins (and all at the same time) is very much higher than is the case with many individual genes. The methods we wish to develop here will extend the range of diseases that may be treated by gene therapy.</gtr:abstractText><gtr:technicalSummary>2A and 2A-like sequences are short, oligopeptide, sequences that mediate a co-translational cleavage at their own C-termini: they are used in gene therapy and other biomedical applications to concatenate multiple cistrons into a single open reading frame. Multiple proteins may, therefore, be co-expressed using from single transgene. We have discovered that sequences immediately upstream of 2A may inhibit the cleavage of proteins targeted to the exocytic pathway. Since ~40% of human proteins are (at least initially) translocated into the ER, gene therapies will inevitably involve the co-expression of such proteins. Our data strongly suggest an interaction between the nascent protein and the translocon pore is responsible for this inhibition. This application seeks to perform a fine mapping of the inhibitory interactions and through a program of screening site-directed mutants/insertions to identify methods of achieving high-level 2A-mediated cleavage of such proteins. The partition of proteins (derived from 2A-mediated cleavage)between the exocytic pathway and the cytoplasm will be measured to compare the the relative efficiencies of different 2A-linker sequences. The aim is to develop the technology to provide gene therapists with a complete tool-kit for protein co-expression.</gtr:technicalSummary><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>343784</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mutations have been made in the 2A oligopeptide sequence which alter the 'cleavage' activity (producing different levels of translational 'recoding'). These clones have been made freely available to other researchers. Guides how to use the 2A protein co-expression system and a bibliography of '2A-users' (plus the different applications of 2A) and maintained and continulally updated on my research web pages.</gtr:description><gtr:id>B0D4B0E7-11D1-4AE2-A372-97FCDC24EED9</gtr:id><gtr:impact>The 2A sequence has been used very widely in biomedicine e.g cancer gene therapies (adodptive cell therapies), production of human pluripotent stem cells, genome editing technologies, etc. We continue to refine this system and to identify new 2A-like sequences to improve the 2A-mediated co-expression of multiple proteins within the same cell.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cDNA clones</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.st-andrews.ac.uk/ryanlab/Index.htm</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/275D3CFF-0BE9-4F60-8BD8-93692A4BE405"><gtr:id>275D3CFF-0BE9-4F60-8BD8-93692A4BE405</gtr:id><gtr:title>The protein coexpression problem in biotechnology and biomedicine: virus 2A and 2A-like sequences provide a solution</gtr:title><gtr:parentPublicationTitle>Future Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72d83583aeb67aefbaddfe7dc1bab6e7"><gtr:id>72d83583aeb67aefbaddfe7dc1bab6e7</gtr:id><gtr:otherNames>Luke G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/93FA2C9F-E2B7-4F6D-8A9D-F8DCA5ADF194"><gtr:id>93FA2C9F-E2B7-4F6D-8A9D-F8DCA5ADF194</gtr:id><gtr:title>Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications.</gtr:title><gtr:parentPublicationTitle>BMC biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a1d9d791366c052f444da78061c166d"><gtr:id>3a1d9d791366c052f444da78061c166d</gtr:id><gtr:otherNames>Minskaia E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1472-6750</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8073192D-AC91-45EA-B246-DC2F38A32D9D"><gtr:id>8073192D-AC91-45EA-B246-DC2F38A32D9D</gtr:id><gtr:title>Optimisation of the 'FMDV' 2A Co-Expression System for Gene Therapies</gtr:title><gtr:parentPublicationTitle>MOLECULAR THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d99fd66d4845336eb4fa7781c0bd90f"><gtr:id>7d99fd66d4845336eb4fa7781c0bd90f</gtr:id><gtr:otherNames>Minskaia Ekaterina</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7CCCB0EB-1682-4FEC-98BF-086793D622C1"><gtr:id>7CCCB0EB-1682-4FEC-98BF-086793D622C1</gtr:id><gtr:title>Protein coexpression using FMDV 2A: effect of &amp;quot;linker&amp;quot; residues.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3a1d9d791366c052f444da78061c166d"><gtr:id>3a1d9d791366c052f444da78061c166d</gtr:id><gtr:otherNames>Minskaia E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901002</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>